Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P05231 (interleukin-6)
 23,907 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To study the role of soluble interleukin-6 receptor (sIL-6R) during pregnancy, sIL-6R levels in the sera of pregnant women in the first, second, and third trimesters were determined and found to remain unchanged during pregnancy, but were significantly higher than those in nonpregnant women in the follicular, ovulatory, and luteal phases of the menstrual cycle (P < 0.001). IL-6 levels, however, in the sera of pregnant women at all trimesters showed no difference from those in nonpregnant women at any stage of the menstrual cycle. Recombinant sIL-6R (rsIL-6R) augmented hCG production by rIL-6-stimulated trophoblasts dose dependently, but failed to enhance hCG production by unstimulated trophoblasts. rIL-6- and rsIL-6R-induced hCG production was significantly blocked by anti-IL-6R antibody, PM1; antisignal transducing glycoprotein 130 (gp130) antibody, GPX7; or a tyrosine kinase inhibitor, genistein. Thus, sIL-6R in serum from pregnant women forms a complex with placental and decidual IL-6 in a manner similar to trophoblast membrane-bound IL-6R. These two discrete types of IL-6R and IL-6 complex might act cooperatively by binding to gp130 and subsequently evoking tyrosine kinase activity in the trophoblasts to produce hCG in vivo.
 ...
PMID:Soluble interleukin-6 (IL-6) receptor in the sera of pregnant women forms a complex with IL-6 and augments human chorionic gonadotropin production by normal human trophoblasts through binding to the IL-6 signal transducer. 755 74

AML-193 is a cytokine-dependent human leukemia cell line established from the bone marrow of an M5-type acute monocytic leukemia (AML) patient. The effect of recombinant human interleukin-6 (rhIL-6) on the proliferation of AML-193 cells was investigated. Both granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and rhIL-3 promoted the DNA synthesis and growth of AML-193 cells in vitro. rhIL-6 alone did not support the growth of AML-193 cells, yet pretreatment of AML-193 cells with rhIL-6 markedly enhanced their proliferative response to subsequent rhGM-CSF or rhIL-3 stimulation. The growth-promoting effect induced by rhIL-6 was attributable in part to the upregulation of GM-CSF receptors on AML-193 cells; treatment of AML-193 cells with rhIL-6 for 24 to 48 hours greatly increased their GM-CSF binding activity, which occurred in a dose-dependent manner. Both the growth-promoting and receptor-upregulating effects induced by rhIL-6 could be blocked by treating AML-193 cells with neutralizing anti-gp130 antibodies (GPX7). Treatment of AML-193 cells with anti-gp130 antibodies alone also led to a notable decline in GM-CSF binding activity, suggesting a possible role of gpl30 in regulating the expression of GM-CSF receptors. When AML-193 cells were starved in cytokine-free medium and then restimulated with rhGM-CSF, a rapid increase (5 minutes) in lyn kinase activity was observed. A similar upregulation of lyn kinase activity by rhIL-6 treatment also was noted in AML-193 cells, but only after a prolonged incubation of the cells with rhIL-6 (>24 hours). These findings show that the growth-promoting effects of rhIL-6 are mediated through the upregulation of GM-CSF receptors on AML-193 cells by mechanisms that appear to involve the activation of both gp130 and lyn kinase.
 ...
PMID:Regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human myeloid leukemia cell line (AML-193) by interleukin-6. 864 72

We examined the effects of a monoclonal antihuman gp130 antibody (GPX7), which is known to inhibit interleukin-6 (IL-6) and leukemia inhibitory factor-mediated responses in human cells on the bone metabolism in normal and ovariectomized (OVX), 7-month-old, Wistar rats for 8 weeks. After confirming the cross-reactivity of the antibody in suppressing the IL-6-mediated proliferation of rat liver cells, GPX7 was injected once a week at doses of 1 (low dose) or 4 (high dose) mg/kg body weight (BW). In the lumbar body, bone mineral density values and the trabecular bone volume (BV/TV) were maintained in the GPX7 groups. The values of the trabecular osteoclast surface and number in the GPX7 high-dose group were significantly smaller than those in the OVX controls. The double-labeled surface and bone formation rates in the GPX7 high-dose group were significantly increased. In the proximal tibia, however, the bone mineral content and BV/ TV values in the GPX7 groups were smaller, but the trabecular thickness value in the GPX7 high-dose group was larger than in the OVX control. The single-labeled surface in the GPX7 high-dose group was significantly larger than that in the OVX control rats. Though the parameter values of trabecular osteoclasts were apparently smaller, the differences were not significant. 17-beta estradiol (0.125 mg/kg BW a week) administration prevented the bone loss by reducing the parameters of bone formation and resorption in both the lumbar and the proximal tibia. The antibody administration to the normal rats did not cause any significant changes in the parameters of bone mass and turnover. These data demonstrate that while GPX7 modulates the bone turnover after ovariectomy in rats, it does not compensate for the action of estrogen after ovariectomy in rats.
 ...
PMID:Effect of monoclonal anti-human gp130 antibody (GPX7) on bone turnover in normal and ovariectomized rats. 950 56